Document Detail


Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
MedLine Citation:
PMID:  23322524     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This trial compared 6 cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of 3 cycles of FEC followed by 3 cycles of docetaxel (FEC-D) as adjuvant treatment for women with node-positive or/and T3 or T4 breast cancer. Between January 2006 and January 2010, 657 patients with operable breast cancer were randomly assigned to either FEC every 21 days for 6 cycles, or 3 cycles of FEC followed by 3 cycles of docetaxel, both given every 21 days. Radiotherapy was mandatory for all patients who had undergone breast conserving surgery. Radiation to the chest wall, supraclavicular area, was recommended following mastectomy. Hormone-receptor-positive patients received tamoxifen for 5 years after chemotherapy. The primary end point was 5-year disease-free survival (DFS). Median follow-up was 61 months. Five-year DFS rates were 74 % with FEC and 78 % with FEC-D (P = 0.013). Multivariate analysis adjusted for prognostic factors showed a 17 % reduction in the relative risk of relapse with FEC-D. Five-year overall survival rates were 85 % with FEC and 89.4 % with FEC-D, demonstrating a 27 % reduction in the relative risk of death (P = 0.014). The incidence of grade 3-4 neutropenia, the need for hematopoietic growth factor, and incidence of nausea/vomiting were higher with FEC. Docetaxel was associated with more febrile neutropenia, stomatitis, edema, and nail disorders. Though rare overall, there were fewer cardiac events after FEC-D, attributable mainly to the lower anthracycline cumulative dose. Sequential adjuvant chemotherapy with FEC followed by docetaxel significantly improves disease-free and overall survival in node-positive or/and T3 or T4 breast cancer patients. Although the magnitude of the benefit observed with FEC-D, differences in the toxicity profiles of FEC and FEC-D may influence the choice of treatment for patients.
Authors:
H Sakr; R H Hamed; A H Anter; T Yossef
Related Documents :
269664 - Blast crisis of chronic granulocytic leukemia. morphologic variants and therapeutic imp...
23274534 - Survival after definitive (chemo)radiotherapy in esophageal cancer patients: a populati...
23100164 - Survival benefit with salvage radiotherapy for patients with locoregionally recurrent e...
24554104 - Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: ...
24931464 - Low expression of microrna-146b-5p and microrna-320d predicts poor outcome of large b-c...
9081374 - Loss of heterozygosity at the dcc gene locus is not crucial for the acquisition of meta...
Publication Detail:
Type:  Journal Article     Date:  2013-01-16
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  457     Citation Subset:  IM    
Affiliation:
Department of Clinical Oncology and Nuclear Medicine, Mansoura University, Mansoura, Egypt.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer.
Next Document:  BAG-1 expression in human meningioma and correlation with clinical characteristics.